This inventor holds 66 USPTO granted patents, primarily in Leukotriene Antagonists (CPC class 5143). Top assignees: Smithkline Corporation, Smithkline Beecham Corporation, Smithkline Beckman Corporation. Active years: 1976-2002.
Inventors with similar research interests:
Location History:
- Cornwell Heights, PA (US) (1976)
- Cornwall Heights, PA (US) (1976 - 1978)
- Cornwells Heights, PA (US) (1976 - 1978)
- Delran, NJ (US) (1976 - 1992)
- Downingtown, PA (US) (1989 - 2002)
- Downington, PA (US) (1991 - 2002)
Company Filing History:
31 out of 344Â 
23 out of 2,198Â 
10 out of 207Â 
Years Active: 1976-2002
Areas of Expertise:
As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I will create an article about inventor John G Gleason based on the provided data.
Title: The Innovations and Career of John G Gleason
Introduction:
John G Gleason, a prolific inventor hailing from Delran, New Jersey, has made significant contributions to the field of biotechnology. With an impressive portfolio of 66 patents, his innovative spirit has led to groundbreaking advancements in the medical and pharmaceutical industries.
Latest Patents:
Among his latest patents is the development of agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal. This technology targets various dimeric cell surface receptors, including crucial proteins like granulocyte colony-stimulating factor and insulin receptor, offering promising applications in leukocyte production enhancement and infection treatment. Additionally, Gleason's work on IL-8 receptor antagonists showcases his commitment to combatting Interleukin-8 mediated diseases through novel compounds.
Career Highlights:
Throughout his career, John G Gleason has left an indelible mark on prominent companies in the field. His tenure at SmithKline Corporation and SmithKline Beecham Corporation, now known as GlaxoSmithKline, has been marked by groundbreaking research and innovative solutions that have reshaped the industry's landscape.
Collaborations:
Collaboration has been a key aspect of Gleason's success, with esteemed coworkers such as Ralph F Hall and Kenneth G Holden contributing to his endeavors. Their combined expertise and dedication have led to the development of cutting-edge technologies that promise to revolutionize healthcare practices.
Conclusion:
In conclusion, John G Gleason's pioneering work in biotechnology underscores his status as a visionary inventor. His multitude of patents and collaborations with industry stalwarts reflect a career dedicated to pushing the boundaries of scientific innovation. Gleason's legacy serves as an inspiration for aspiring inventors and underscores the transformative power of innovation in shaping the future of healthcare.